Related Experiment Video
Updated: Mar 18, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing
Alessandra Fabi1, Paola Malaguti2, Sabrina Vari2
1Division of Medical Oncology 1, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. alessandra.fabi@virgilio.it.
Abstract:
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced HER2-positive breast cancer (BC).HER-2 targeted therapies represent a major step forward in achieving the goal of delivering individualized targeted therapy for BC, and trastuzumab was the first anti-HER-2 strategy to be approved for treatment of HER-2 positive BC. This review discusses the treatment of metastatic HER2-positive BC and describes efficacy and safety of novel anti-HER2 target therapies in first-line metastatic settings and the future challenges include refining such treatments, reducing toxicity and simultaneously developing innovative therapies. Furthermore, combinations of trastuzumab and drugs targeting the downstream pathway are described.In the next future will be possible to use an ample armamentarium of combination therapies directed against HER2 and key signaling components integrated in the HER network. This approach will allow clinicians to tailor the management of the individual patient on the basis of tumor- specific biomarker profiles.There is an urgent need for prospective biomarker-driven trials to identify patients for whom targeting is cost-effective.
Insights
HER2-targeted therapies, including trastuzumab, have transformed HER2-positive breast cancer (BC) treatment. Future strategies focus on novel combinations and biomarker-driven trials for personalized care.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The discovery of human epidermal growth factor receptor 2 (HER2) has revolutionized HER2-positive breast cancer (BC) treatment.
- HER2-targeted therapies, starting with trastuzumab, have significantly improved outcomes in early-stage and advanced BC.
Purpose of the Study:
- To review the treatment landscape for metastatic HER2-positive BC.
- To discuss the efficacy and safety of novel anti-HER2 therapies in the first-line metastatic setting.
- To explore future challenges and opportunities in HER2-targeted therapy.
Main Methods:
- Review of current literature on HER2-targeted therapies for metastatic breast cancer.
- Discussion of novel anti-HER2 agents and combination strategies.
- Analysis of future directions, including biomarker-driven trials.
Main Results:
- HER2-targeted therapies have dramatically improved clinical outcomes for HER2-positive BC patients.
- Novel anti-HER2 therapies show promise in first-line metastatic settings.
- Combination therapies targeting HER2 and downstream pathways are emerging.
Conclusions:
- Personalized management of HER2-positive BC will be enhanced by tailored combination therapies based on tumor biomarkers.
- Refining treatments, reducing toxicity, and developing innovative therapies are crucial future challenges.
- Prospective biomarker-driven trials are urgently needed to optimize cost-effective HER2-targeted treatment selection.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:01Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers